--- title: "SURMOUNT-3: Tirzepatide Phase 3 Results | Primara Labs" url: https://www.primaralabs.com/research/trials/surmount-3 source: Primara Labs, markdown mirror of the HTML page --- # SURMOUNT-3 In SURMOUNT-3, a phase 3 trial of tirzepatide in adults with BMI of 30 or more, or 27 or more with at least one obesity-related complication (excluding diabetes), who achieved 5.0% or more weight reduction after a 12-week intensive lifestyle intervention (n=579), mean body weight changed by -18.4% on maximum tolerated dose (10 or 15 mg) over 72 weeks, against +2.5% on placebo (treatment-regimen estimand; Wadden TA et al. Nat Med 2023 (SURMOUNT-3)). Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked. Updated 24 September 2026 Tirzepatide Explained: SURMOUNT, SURPASS and Philippines Status1:58·[Transcript and chapters](https://www.primaralabs.com/videos/tirzepatide) ## Results Mean percent change in body weight by arm, as each source reports it. Navy bars are the trial arms, grey bars the comparator. Bars from different trials are not a head-to-head comparison: populations, durations and estimands differ. ## Side effects reported In SURMOUNT-3, discontinuation because of adverse events was 10.5% on maximum tolerated dose (10 or 15 mg), against 2.1% on placebo. The most frequently reported adverse events were nausea in 39.7% on maximum tolerated dose (10 or 15 mg) against 14.0% on placebo, diarrhoea in 31.0% on maximum tolerated dose (10 or 15 mg) against 9.2% on placebo, constipation in 23.0% on maximum tolerated dose (10 or 15 mg) against 6.8% on placebo and vomiting in 18.1% on maximum tolerated dose (10 or 15 mg) against 1.4% on placebo. | Event | Maximum tolerated dose (10 or 15 mg) | Placebo | | --- | --- | --- | | Discontinuation for adverse events | 10.5% | 2.1% | | Nausea | 39.7% | 14.0% | | Diarrhoea | 31.0% | 9.2% | | Constipation | 23.0% | 6.8% | | Vomiting | 18.1% | 1.4% | Design ## Trial design and sources Compound Tirzepatide Phase 3 Population Adults with BMI of 30 or more, or 27 or more with at least one obesity-related complication (excluding diabetes), who achieved 5.0% or more weight reduction after a 12-week intensive lifestyle intervention Participants randomised 579 Duration 72 weeks Primary endpoint Coprimary: additional mean percent weight change from randomization to week 72, and percentage achieving additional weight reduction of 5% or more Estimand treatment-regimen Read out 15 October 2023 Enrolled participants who had lost 5% or more in a 12-week intensive lifestyle lead-in; figures are the additional change from randomisation. The placebo arm regained weight. - Wadden TA et al. Nat Med 2023 (SURMOUNT-3) [open](https://doi.org/10.1038/s41591-023-02597-w) · checked 23 September 2026 - ClinicalTrials.gov NCT04657016 [open](https://clinicaltrials.gov/study/NCT04657016) · checked 23 September 2026 - Registry: NCT04657016 Questions ## SURMOUNT-3, answered ### What did SURMOUNT-3 find? In SURMOUNT-3, a phase 3 trial of tirzepatide in adults with BMI of 30 or more, or 27 or more with at least one obesity-related complication (excluding diabetes), who achieved 5.0% or more weight reduction after a 12-week intensive lifestyle intervention (n=579), mean body weight changed by -18.4% on maximum tolerated dose (10 or 15 mg) over 72 weeks, against +2.5% on placebo (treatment-regimen estimand; Wadden TA et al. Nat Med 2023 (SURMOUNT-3)). ### What side effects were reported in SURMOUNT-3? In SURMOUNT-3, discontinuation because of adverse events was 10.5% on maximum tolerated dose (10 or 15 mg), against 2.1% on placebo. The most frequently reported adverse events were nausea in 39.7% on maximum tolerated dose (10 or 15 mg) against 14.0% on placebo, diarrhoea in 31.0% on maximum tolerated dose (10 or 15 mg) against 9.2% on placebo, constipation in 23.0% on maximum tolerated dose (10 or 15 mg) against 6.8% on placebo and vomiting in 18.1% on maximum tolerated dose (10 or 15 mg) against 1.4% on placebo. Related ## More on tirzepatide - [TRIUMPH-5](https://www.primaralabs.com/research/trials/triumph-5) - [SURMOUNT-1](https://www.primaralabs.com/research/trials/surmount-1) - [SURMOUNT-2](https://www.primaralabs.com/research/trials/surmount-2) - [SURMOUNT-4](https://www.primaralabs.com/research/trials/surmount-4) - [SURMOUNT-5](https://www.primaralabs.com/research/trials/surmount-5) - [Evidence Map: Tirzepatide](https://www.primaralabs.com/research/evidence#tirzepatide) - [Tirzepatide 15mg](https://www.primaralabs.com/marketplace/tirzepatide-15mg)